Research Reports

Q1 2025 net sales of $483M, rising 7% at CER (CEO) (prepared)
Adjusted diluted EPS of $0.50 at CER, ahead of outlook for at least $0.50 (CEO)
Diagnostic Solutions sales +11% CER, driven by QIAstat-Dx (+37%) and QuantiFERON (+16%) (CFO)
PCR Technologies +14% CER, led by QIAcuity digital PCR system and consumables (CFO)
Sample Technology sales -1% CER, with lower instrument sales but high single-digit automation consumable growth in EMEA (CFO)
Genomics/NGS sales -2% CER; QIAGEN Digital Insights high single-digit CER growth (CFO)
Adjusted operating income margin 29.8% of sales, up >4pp from Q1 2024 (CFO)
Operating cash flow $140M (Q1 2025) vs $133M (Q1 2024); free cash flow $96M (CFO)
DSO improved to 55 days (Q1 2025) from 58 days (Q1 2024); inventory days 175 vs 221 (CFO)
Proposed annual cash dividend of $0.25 per share; seeking approval for up to $500M synthetic share repurchase (CEO)

Period	Metric	Guidance
FY 2025	Net sales growth at CER	~4% (~5% core portfolio excluding NeuMoDx/DiaLunox) (CFO)
FY 2025	Adjusted EPS at CER	~$2.35 (~8% CER growth vs 2024) (CFO)
Q2 2025	Net sales growth at CER	at least 5% (at least 5% core portfolio) (CFO)
Q2 2025	Adjusted EPS	at least $0.60 (vs $0.55 in Q2 2024) (CFO)

"Qiagen delivered a very good and solid start to 2025, once again demonstrating the resilience and strength of our business." (CEO)
"We exceeded our outlook for both net sales and adjusted earnings even as we continue to operate in a quite complex macro environment." (CEO)
"We delivered a significant improvement in profitability. Our adjusted operating income margin rose to 29.8% of sales, up more than four percentage points." (CFO)
"In light of this strong progress... we are reviewing our target for an adjusted operating income margin of at least 31%, well ahead of the original time line for 2028." (CFO)
"Our results for the first quarter and the latest reviews with our teams give us confidence in our strategy, our execution and our ability to deliver on these targets." (CFO)

Metric	Value	Speaker/Context
Net Sales	$483M	Q1 2025, CEO (prepared)
Net Sales Growth (CER)	+7%	vs Q1 2024, CEO
Adjusted Diluted EPS	$0.50	Q1 2025, CEO
Adjusted Operating Income Margin	29.8%	Q1 2025, CFO
Operating Cash Flow	$140M	Q1 2025, CFO
Free Cash Flow	$96M	Q1 2025, CFO
Days Sales Outstanding	55 days	Q1 2025, CFO (vs 58 days Q1 2024)
Inventory Days	175 days	Q1 2025, CFO (vs 221 days Q1 2024)

Topic: 中国业务与数字洞察（QDI）前景
Key points:
- 中国占公司销售额 4%，市场虽大但复杂、风险高，非优先重点；当地偏好本土制造，持续影响生命科学与诊断业务；QuantiFERON 每季度仍增长。
- QDI 在 Q1 表现优于 Q4 和 Q3（临床与发现板块均改善），正在向 SaaS 商业模式转型，全年目标高个位数增长，预计 2025 年内完成转型。
Mgmt stance: 中性偏谨慎（中国业务因政策风险维持低优先级；QDI 转型进展积极，但需全年验证）。

Topic: 样本制备（Sample Tech）自动化仪器增长前景
Key points:
- 新系统（如 QIAsymphony、QIAsprint）非“me-too”产品，具创新性（成本节约、缩短时间、易用），已获液态活检与大型药企客户正面反馈。
- 若资本支出环境持续疲软，2025–2026 年可能延迟部分订单；但长期 2028 年增长目标不变，因产品价值差异化。
Mgmt stance: 谨慎乐观（依赖创新价值穿透资本约束，但短期有执行风险）。